Biology News
The cryo-electron microscopy structure of huntingtin - Phys.Org

The protein huntingtin consists of three flexible regions, shown in red, yellow and blue. Together with its interaction partner HAP40 (purple) huntingtin is more stable. This enabled the scientists to deduce their three-dimensional …more. Mutations on ...
EurekAlert (press release)

Cell biology: Scientists fill in a piece of the copper transport puzzle - Science Daily

Science Daily
Cell biology: Scientists fill in a piece of the copper transport puzzle. Date: February 14, 2018; Source: American Society for Biochemistry and Molecular Biology; Summary: Researchers have identified the protein that carries copper into mitochondria ...

Neurobiology ELISA Kits Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions ... - The Financial

The Financial
Global Neurobiology ELISA Kits Market 2017-2022 offers comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the market and their ...

Protein Therapeutics Discovery and Development

Fulshear - United States

This conference will explore the therapeutic applications of proteins, the discovery and design of therapeutics, the problems associated with protein based drugs and new tools and strategies in process development.

Evidence of a new type of protein-protein interaction
Russian Federation

Desensitized actomyosin blocks Ca2+-sensitivity of the natural one. Physiological Chemistry and Physics and Medical NMR, 32: 167-179, 2000.

Silence Therapeutics

Developing RNAi therapeutics using siRNA-based technology called AtuRNAi.

Sirna Therapeutics, Inc.
United States

Develop treatments based on RNAi technology for asthma, diabetes, hepatitis C, macular degeneration and Huntington's Disease. Includes product pipeline, overview of company with research and manufacturing in Boulder, Colorado, headquartered in San Francisco, California.

RNAi Therapeutics: How Likely, How Soon?
United States

Review article from PLoS Biology journal. Describes mechanism of RNA Interference, potential applications towards therapeutics, and current problems associated with delivery.

Cellerant Therapeutics, Inc.
United States

Products based on the regulation of the human haematopoietic (blood-forming) system.

Cytori Therapeutics, Inc.
United States

Developing proprietary, cell-based therapies from adult adipose tissue, targeting cardiovascular disease, orthopedic conditions, gastrointestinal disorders and autologous reconstructive surgery. International contacts with headquarters in San Diego, California.

RegenoCELL Therapeutics, Inc.
United States

Provides information targeted at investors, about stem cell treatments for congestive heart failure and peripheral artery disease.

VistaGen Therapeutics, Inc.
United States

Developing new generation drug candidates, applying in vitro embryonic technologies to disorders of the central nervous system, diabetes and other metabolic syndromes. Profile and contacts in South San Francisco, California.

Collateral Therapeutics
United States

A product-driven cardiovascular gene therapy company, focused on the discovery, development and commercialization of novel and innovative non-surgical gene therapy products.

Introgen Therapeutics, Inc.
United States

Focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.